Search research articles
Contact Us
Filters
Showing results (271-280 of 293) with videos related to
Page
of 30
Sort By:
BMJ Open
|
April 24, 2026
Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial
Dianne L Carey, Golo Ahlenstiel, Fabienne Brilot, et al.
AIDS (London, England)
|
July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infection
Marianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Trials
|
April 29, 2026
Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk
Phyo Pyae Nyein, Hila Haskelberg, Marianne Martinello, et al.
Nature Communications
|
April 17, 2024
Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection
Chansavath Phetsouphanh, Brendan Jacka, Sara Ballouz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 10, 2024
Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort
Brendan L Harney, Rachel Sacks-Davis, Daniela K van Santen, et al.
Hepatology Communications
|
February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review
Sofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 3, 2020
Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial
Joseph S Doyle, Daniela K van Santen, David Iser, et al.
AIDS (London, England)
|
November 22, 2024
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa
Emmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, et al.
Gut
|
February 3, 2026
Gut health is associated with clonal haematopoiesis in older adults with and without HIV: the ARCHIVE longitudinal cohort study
Mark W Donoghoe, Hossain Ms Sazzad, Win Min Han, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 27, 2025
A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT study
Phyo Pyae Nyein, Margaret Borok, Nnakelu Eriobu, et al.
Page
of 30
Search research articles
Search
Showing results (271-280 of 293) with videos related to
Sort By:
Page
of 30
BMJ Open
|
April 24, 2026
Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial
Dianne L Carey, Golo Ahlenstiel, Fabienne Brilot, et al.
AIDS (London, England)
|
July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infection
Marianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Trials
|
April 29, 2026
Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk
Phyo Pyae Nyein, Hila Haskelberg, Marianne Martinello, et al.
Nature Communications
|
April 17, 2024
Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection
Chansavath Phetsouphanh, Brendan Jacka, Sara Ballouz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 10, 2024
Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort
Brendan L Harney, Rachel Sacks-Davis, Daniela K van Santen, et al.
Hepatology Communications
|
February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review
Sofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 3, 2020
Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial
Joseph S Doyle, Daniela K van Santen, David Iser, et al.
AIDS (London, England)
|
November 22, 2024
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa
Emmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, et al.
Gut
|
February 3, 2026
Gut health is associated with clonal haematopoiesis in older adults with and without HIV: the ARCHIVE longitudinal cohort study
Mark W Donoghoe, Hossain Ms Sazzad, Win Min Han, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 27, 2025
A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT study
Phyo Pyae Nyein, Margaret Borok, Nnakelu Eriobu, et al.
Page
of 30